List view / Grid view

News

Custom to build £20 million Pharmaceutical Innovation Centre in Brighton

17 February 2017 | By Niamh Marriott, Digital Editor

Custom Pharma Services, the Brighton based CDMO, is pleased to announce the commencement of the building work on its £20 million Pharmaceutical Innovation Centre (PIC) in Moulsecoomb, Brighton. The Custom PIC will house the contract development, clinical and commercial manufacturing teams in a new, purpose built facility. This investment is…

FDA approves new psoriasis drug that induced suicide in trial

17 February 2017 | By Niamh Marriott, Digital Editor

The US Food and Drug Administration (FDA) has approved Valeant’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or…

EC approves Eli Lilly’s rheumatoid arthritis drug

16 February 2017 | By Niamh Marriott, Digital Editor

The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA), in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).

Nanobiotix appoints Oncology industry veteran as Chief Operating Officer

7 February 2017 | By Niamh Marriott, Digital Editor

Nanobiotix, a late clinical-stage nanomedicine company, announced the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer. Mr Dostie will lead Nanobiotix’s operations, including development, manufacturing, market access and sales, for their lead product NBTXR3, which could obtain a CE Mark approval in…